Literature DB >> 17142738

Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.

Anna Charalambous1, Margarita Oks, Godwin Nchinda, Sayuri Yamazaki, Ralph M Steinman.   

Abstract

To determine whether strong CD4+ T cell immunity could be induced to a nonmutated self protein that is important for tumorigenesis, we selectively targeted the xenogeneic form of survivin, a survival protein overexpressed in tumors, to maturing dendritic cells in lymphoid tissues. Dendritic cell targeting via the DEC205 receptor in the presence of anti-CD40 and poly(I:C) as maturation stimuli, induced strong human and mouse survivin-specific CD4+ T cell responses, as determined by IFN-gamma, TNF-alpha, and IL-2 production, as well as the development of lytic MHC class II-restricted T cells and memory. Immunity was enhanced further by depletion of CD25+foxp3+ cells before vaccination. anti-DEC205-human survivin was superior in inducing CD4+ T cell responses relative to other approaches involving survivin plasmid DNA or survivin peptides with adjuvants. However, we were unable to induce CD8+ T cell immunity to survivin by two doses of DEC205-targeted survivin or the other strategies. Therefore, significant CD4+ T cell immunity to a self protein that is overexpressed in most human cancers can be induced by DEC205 targeting of the Ag in its xenogeneic form to maturing DCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142738     DOI: 10.4049/jimmunol.177.12.8410

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Trial Watch: Monoclonal antibodies in cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Jessica Zucman-Rossi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

Review 3.  Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance.

Authors:  Christopher J Nirschl; Niroshana Anandasabapathy
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 4.  Enhancement of dendritic cells as vaccines for cancer.

Authors:  Meghan E Turnis; Cliona M Rooney
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

5.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

6.  DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Authors:  Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; André Maaske; Vladimir Temchura; Vanessa Heinecke; Drew Hannaman; Jan Buer; Christina Ehrhardt; Wiebke Hansen; Klaus Überla; Matthias Tenbusch
Journal:  Immunology       Date:  2015-04-30       Impact factor: 7.397

7.  Inflammatory spleen monocytes can upregulate CD11c expression without converting into dendritic cells.

Authors:  Scott B Drutman; Julia C Kendall; E Sergio Trombetta
Journal:  J Immunol       Date:  2012-03-21       Impact factor: 5.422

Review 8.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

9.  The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.

Authors:  Bei Wang; Janelle M Y Kuroiwa; Li-Zhen He; Anna Charalambous; Tibor Keler; Ralph M Steinman
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

10.  Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.

Authors:  Douglas C Palmer; Chi-Chao Chan; Luca Gattinoni; Claudia Wrzesinski; Chrystal M Paulos; Christian S Hinrichs; Daniel J Powell; Christopher A Klebanoff; Steven E Finkelstein; Robert N Fariss; Zhiya Yu; Robert B Nussenblatt; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.